Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves lean mass and enhances fat loss, offering a potential advancement in obesity treatment
The researchers noted that each study population, the semaglutide group and the type 2 diabetes group had similarly matched demographics, medical histories, lifestyles, and histories of mental health conditions, including suicidal ideation and behavior
,
Once-weekly dosing is preferred by 68% of patients, improving adherence rates by 32% compared to daily injections
But rapid weight loss can bring a previously hidden androgenetic alopecia to the surface
